CN Patent
CN104370828B — 用作raf激酶抑制剂的嘧啶衍生物
Assigned to Dot Therapy 1 Co · Expires 2017-01-18 · 9y expired
What this patent protects
本发明提供用作Raf蛋白激酶抑制剂的化合物。本发明也提供它们的组合物和治疗Raf‑介导的疾病的方法。
USPTO Abstract
本发明提供用作Raf蛋白激酶抑制剂的化合物。本发明也提供它们的组合物和治疗Raf‑介导的疾病的方法。
Drugs covered by this patent
- Ojemda (TOVORAFENIB) · Day One Biopharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.